Follow-The-Filings

Security

AZN

Astrazeneca PLC · SPONSORED ADR

Equity holders as of 2025 Q4 (each manager’s latest book)

3 owners 16 exits max 0.3% (Two Sigma Investments, LP)

grid → activity → earnings →
owners 3
max % 0.3%
tracked value $318M
qoq R 1 E 16

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Two Sigma Investments, LP 2025 Q4 0.3% Exit -0.28 pp 2,180,476 $200M hist
Norges Bank 2025 Q4 0.0% Exit -0.01 pp 1,276,181 $117M hist
Joel Greenblatt - Gotham Asset Management, LLC 2026 Q1 stale 0.0% Reduce 0.00 pp 2,868 $566 hist
Lewis Sanders - Sanders Capital, LLC exited 2026 Q1 last 2025 Q4 1.5% Exit -1.50 pp 14,139,408 $1.3B hist
Sarah Ketterer - Causeway Capital Management LLC exited 2026 Q1 last 2025 Q4 1.3% Exit -1.28 pp 1,010,898 $93M hist
Ken Fisher - Fisher Asset Management, LLC exited 2026 Q1 last 2025 Q4 0.7% Exit -0.68 pp 21,601,433 $2B hist
Bill Nygren / Oakmark - Harris Associates L P exited 2026 Q1 last 2025 Q4 0.4% Exit -0.43 pp 3,729,731 $343M hist
Natixis Advisors, LLC exited 2026 Q1 last 2025 Q4 0.3% Exit -0.27 pp 2,053,511 $189M hist
Steve Cohen - Point72 Asset Management, L.P. exited 2026 Q1 last 2025 Q4 0.2% Exit -0.19 pp 1,852,741 $170M hist
Dmitry Balyasny - Balyasny Asset Management L.P. exited 2026 Q1 last 2025 Q4 0.1% Exit -0.13 pp 1,078,380 $99M hist
Israel Englander - Millennium Management LLC exited 2026 Q1 last 2025 Q4 0.1% Exit -0.09 pp 2,396,943 $220M hist
Ron Baron - Bamco Inc. /NY/ (Baron Capital) exited 2026 Q1 last 2025 Q4 0.0% Exit -0.03 pp 135,025 $12M hist
Ken Griffin - Citadel Advisors LLC exited 2026 Q1 last 2025 Q4 0.0% Exit -0.01 pp 840,134 $77M hist
Dodge & Cox exited 2026 Q1 last 2025 Q4 0.0% Exit -0.01 pp 121,043 $11M hist
Cliff Asness - Aqr Capital Management LLC exited 2026 Q1 last 2025 Q4 0.0% Exit -0.01 pp 111,959 $10M hist
Murray Stahl - Horizon Kinetics Asset Management LLC exited 2026 Q1 last 2025 Q4 0.0% Exit -0.01 pp 10,994 $1M hist
Ancora Advisors LLC exited 2026 Q1 last 2025 Q4 0.0% Exit -0.01 pp 3,254 $299 hist
D. E. Shaw & Co., Inc. exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 41,437 $4M hist
Marshall Wace - Marshall Wace, LLP exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 10,920 $1M hist

3 current · 16 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 25 shown

Filed Form Detail Links
6-K DATROWAY APPROVED IN EU FOR TNBC Filing Doc
6-K FORM 6-K Filing Doc
6-K SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS Filing Doc
6-K UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA Filing Doc
6-K ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER Filing Doc
6-K ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR Filing Doc
6-K UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL Filing Doc
4 OWNERSHIP DOCUMENT Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K ADMISSION OF FURTHER SECURITIES TO TRADING Filing Doc
6-K DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC Filing Doc
6-K ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS Filing Doc
4 OWNERSHIP DOCUMENT Filing Doc
6-K TRUQAP APPROVED IN US FOR PROSTATE CANCER Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K ADMISSION OF FURTHER SECURITIES TO TRADING Filing Doc
6-K IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER Filing Doc
6-K US FDA DECISION DATE ON CAMIZESTRANT EXTENDED Filing Doc
6-K CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU Filing Doc
6-K ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS Filing Doc
6-K DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC Filing Doc
4 OWNERSHIP DOCUMENT Filing Doc
6-K ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS Filing Doc
6-K BAXFENDY APPROVED IN THE US FOR HYPERTENSION Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc

Updated 14 minutes ago Source: SEC EDGAR submissions All on EDGAR

ownership over time

filing count by report period · click a bar for that quarter’s holders